CureVac to withdraw first-generation COVID-19 vaccine candidate

A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves HermanBERLIN, Oct 12 (Reuters) – CureVac (5CV.DE) will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK (GSK.L) to develop second-generation mRNA vaccine technology instead, the Germany-based biotechnology company said on Tuesday.The company said it will withdraw its first-generation vaccine candidate CVnCoV, which failed late-stage trials with 47% accuracy in June, due to a potential overlap with approval timelines for a second-generation candidate. read more The earliest potential approval of CVnCoV would have come in the second quarter of 2022 when the candidates from the second-generation vaccine program are expected to progress to late-stage clinical development by that time, CureVac said.Reporting by Zuzanna Szymanska
Editing by Riham AlkousaaOur Standards: The Thomson Reuters Trust Principles.

Source link

Leave a Comment

%d bloggers like this: